Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

ells and platelets.

Eight of the 10 patients had high-risk genomic features and no dose-limiting toxicities or serious adverse events had occurred. Mild (grade 1-2) infusion toxicity was observed in three patients. Beginning with the 0.3 mg/kg dose, all eight patients demonstrated evidence of biological activity including high-risk patients. Two patients had partial clearing of leukemia cutis, and the other six had 27% to 94% reduction in peripheral lymphocyte count. One patient had an increase in hemoglobin of 40% and a reduction in lymph nodes of 36%. Two patients had a significant increase in platelet count.

TRU-016 is a humanized SMIP protein therapeutic that targets the CD37 antigen and has shown potent anti-tumor activity in pre-clinical studies. Trubion initiated a Phase 1/2 clinical trial of TRU-016 in March 2008. The open-label clinical trial has two components: a Phase 1 dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016, and a Phase 2 expansion cohort designed to further evaluate safety and estimate clinical activity of TRU-016 in patients with previously treated CLL or small lymphocytic lymphoma (SLL).

Abstract 8571 (May 30, 2009): Evaluation of the Effect of TRU-016 in Combination With Other Therapeutic Drugs in Models of Non-Hodgkin's Lymphoma

In addition, Trubion will also present at the 2009 ASCO Annual Meeting preclinical data evaluating TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine. Drugs were tested alone or in combination with TRU-016 for anti-proliferative effects on cell lines in vitro and on tumors in vivo.

Combination index analyses revealed that TRU-016 is synergistic with rituximab, bendamustine, or rapamycin and additive with doxorubicin in killing NHL cells in vitro. In vivo results show that treatment with the combination of TRU-016
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... -- GenomeDx Biosciences today announced that a new study ... test for prostate cancer, was able to predict rapid ... prostatectomy without adjuvant therapy. Although rapid metastasis in men ... genomics to identify these men who have a highly ... The study has been published online by the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... LA JOLLA, Calif., May 12 TorreyPines,Therapeutics, Inc. (Nasdaq: ... a conference call and audio webcast on Tuesday, May ... with the release of its,financial results for the first ... results at 7:30 a.m. ET on Tuesday, May,13, 2008., ...
... and its biotech ... pipeline, ... today completion of the final phase of its $1 billion,effort to further ... its Indianapolis operations, Lilly officials, along,with participation by Indianapolis Mayor Gregory Ballard, ...
... screening initiative launches in Atlanta and continues for 90 days;, ... in 13 cities ... across the country, ... specialty biopharmaceutical company, today,announced the launch of a 13-city mobile screening ...
Cached Biology Technology:TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... paleontological evidence as a crystal ball, 18 scientists, including ... much worse collision course with Mother Nature than currently ... Earth,s biosphere, a paper just published in Nature ... disciplines, suggest our planet,s ecosystems are careening towards an ...
... Working with researchers at the University of Pittsburgh ... Barbara have found high levels of beneficial omega-3 fatty ... woman as compared to women in the United States. ... journal Maternal and Child Nutrition . The ...
... A team of George Washington University researchers have received ... nuclear reactor cores. The findings of the research have ... the future. Philippe M. Bardet, assistant professor of ... project, and his colleagues, Elias Balaras, associate professor of ...
Cached Biology News:Study predicts imminent irreversible planetary collapse 2UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women 2Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors 2
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
Biology Products: